{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:13:15Z","timestamp":1778487195545,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.leukres.2026.108227","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:44:37Z","timestamp":1775666677000},"page":"108227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy of hypomethylating agents in combination with venetoclax in relapsed\/refractory acute myeloid leukemia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-2924","authenticated-orcid":false,"given":"Brittany","family":"Salter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3072-0717","authenticated-orcid":false,"given":"Sarah","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2668-0449","authenticated-orcid":false,"given":"Tobias","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Garcia-Horton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.leukres.2026.108227_bib1","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108227_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3324\/haematol.2017.168716","volume":"103","author":"Schmid","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.leukres.2026.108227_bib3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/bjh.14107","article-title":"A prognostic model for survival after salvage treatment with FLAG-Ida +\/- gemtuzumab-ozogamicine in adult patients with refractory\/relapsed acute myeloid leukaemia","volume":"174","author":"Bergua","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2026.108227_bib4","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.23.00943","article-title":"Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations","volume":"42","author":"Russell","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.leukres.2026.108227_bib5","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108227_bib6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","article-title":"Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2026.108227_bib7","first-page":"72","article-title":"Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"109","author":"Shahswar","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2026.108227_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.leukres.2026.108227_bib9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.leukres.2026.108227_bib10","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108227_bib11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.leukres.2026.108227_bib12","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.leukres.2026.108227_bib13","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2026.108227_bib14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.25929","article-title":"Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia","volume":"95","author":"Aldoss","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108227_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1370405","article-title":"Efficacy and safety of venetoclax plus hypomethylating agents in relapsed\/refractory acute myeloid leukemia: a multicenter real-life experience","volume":"14","author":"Angotzi","year":"2024","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108227_bib16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1186\/s12885-025-14167-z","article-title":"Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study","volume":"25","author":"Bai","year":"2025","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2026.108227_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061666","article-title":"A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed\/Refractory Acute Myeloid Leukemia","volume":"15","author":"Bang","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.leukres.2026.108227_bib18","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108227_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.leukres.2026.108227_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clml.2024.02.005","article-title":"Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant","volume":"24","author":"Ionescu","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.leukres.2026.108227_bib21","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.18229","article-title":"Hypomethylating agent\/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia","volume":"198","author":"Jamy","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108227_bib22","first-page":"1865","article-title":"Molecular predictors of response and survival in patients with relapsed\/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy","volume":"110","author":"Johnson","year":"2025","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2026.108227_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071734","article-title":"Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience","volume":"14","author":"Labrador","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.leukres.2026.108227_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106317","article-title":"Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study","volume":"91","author":"Lou","year":"2020","journal-title":"Leuk. Res"},{"issue":"22","key":"10.1016\/j.leukres.2026.108227_bib25","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1002\/cncr.33814","article-title":"Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis","volume":"127","author":"Maiti","year":"2021","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.leukres.2026.108227_bib26","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.leukres.2026.108227_bib27","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1080\/10428194.2024.2390574","article-title":"Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study","volume":"65","author":"Pelland","year":"2024","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.leukres.2026.108227_bib28","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ajh.27626","article-title":"Venetoclax\u2013Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective Study","volume":"100","author":"Petit","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108227_bib29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/ejh.14140","article-title":"Azacitidine\u2013venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients","volume":"112","author":"Petit","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108227_bib30","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-019-03719-6","article-title":"Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study","volume":"98","author":"Ram","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108227_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/20406207251372770","article-title":"Real-world outcomes of azacitidine plus venetoclax in acute myeloid leukemia: a multicenter retrospective cohort study from Thailand","volume":"16","author":"Rattanathammethee","year":"2025","journal-title":"Ther. Adv. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108227_bib32","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41375-024-02501-6","article-title":"A novel prognostic risk model for patients with refractory\/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents","volume":"39","author":"Shahswar","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2026.108227_bib33","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2026.108227_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41408-025-01265-1","article-title":"VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed\/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial","volume":"15","author":"Swaminathan","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108227_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.649209","article-title":"Outcomes of Adults With Relapsed\/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center","volume":"11","author":"Tenold","year":"2021","journal-title":"Front Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108227_bib36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.34608","article-title":"AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia","volume":"129","author":"Todisco","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2026.108227_bib37","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.2147\/CMAR.S316561","article-title":"Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting","volume":"13","author":"Tong","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"2","key":"10.1016\/j.leukres.2026.108227_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2024013086","article-title":"Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed\/refractory AML","volume":"9","author":"Unglaub","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108227_bib39","article-title":"Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed\/refractory acute myeloid leukemia","author":"Verdeyen","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2026.108227_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17040586","article-title":"Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed\/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese Patients","volume":"17","author":"Wang","year":"2025","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.leukres.2026.108227_bib41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/joim.13581","article-title":"Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia","volume":"293","author":"Weng","year":"2023","journal-title":"J. Intern Med"},{"issue":"1","key":"10.1016\/j.leukres.2026.108227_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2265206","article-title":"Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed\/refractory acute myeloid leukemia","volume":"28","author":"Xu","year":"2023","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.leukres.2026.108227_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1078-0432.CCR-24-1332","article-title":"Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed\/Refractory AML: A Multicenter Cohort Study","volume":"31","author":"Yu","year":"2025","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.leukres.2026.108227_bib44","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1080\/10428194.2018.1508670","article-title":"FLAG salvage therapy combined with idarubicin in relapsed\/refractory acute myeloid leukemia","volume":"60","author":"Westhus","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2026.108227_bib45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2141.2003.04728.x","article-title":"Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes","volume":"124","author":"Virchis","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108227_bib46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","volume":"80","author":"Wierzbowska","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108227_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2025-6","article-title":"Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","volume":"146","author":"Fathi","year":"2025","journal-title":"Blood"},{"issue":"39","key":"10.1016\/j.leukres.2026.108227_bib48","article-title":"Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study","volume":"97","author":"Xu","year":"2018","journal-title":"Med. (Baltim. )"},{"issue":"1","key":"10.1016\/j.leukres.2026.108227_bib49","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/10428194.2020.1821009","article-title":"Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed\/refractory acute myeloid leukemia","volume":"62","author":"Mushtaq","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.leukres.2026.108227_bib50","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1182\/blood.V108.11.4561.4561","article-title":"Clinical Outcomes in Patients with Relapsed\/Refractory Acute Leukemia Treated with FLAG-IDA Regimen","volume":"108","author":"Basquiera","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2026.108227_bib51","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1182\/blood.V110.11.2866.2866","article-title":"FLAG-IDA Regimen (Fludarabine, Cytarabine, Idarubicin and G-CSF) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"110","author":"Montesinos","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108227_bib52","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41375-022-01786-9","article-title":"Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms","volume":"37","author":"Walti","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2026.108227_bib53","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol."},{"issue":"19","key":"10.1016\/j.leukres.2026.108227_bib54","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1182\/blood.2025028730","article-title":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial","volume":"146","author":"Stelljes","year":"2025","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:07:04Z","timestamp":1778486824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":54,"alternative-id":["S0145212626000718"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108227","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of hypomethylating agents in combination with venetoclax in relapsed\/refractory acute myeloid leukemia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108227"}}